Literature DB >> 1412722

The outcome of pregnancy following renal transplantation--the experience of a single center.

N Muirhead1, A R Sabharwal, M J Rieder, A I Lazarovits, D J Hollomby.   

Abstract

Many centers still recommend avoidance of pregnancy after renal transplantation because of fears for the safety of both mother and fetus. These fears are in part based on a lack of information concerning the effects of newer immunosuppressive drugs such as cyclosporine on the course and outcome of pregnancy. The present study examines the experience of first pregnancies following renal transplantation in a single center, with emphasis on the role of CsA. Data on the first pregnancies of 22 women transplanted between 1977 and 1988 were studied. The mean age of patients at the time of transplant was 23.4 +/- 3.1 years and interval from transplant to pregnancy was 34.5 +/- 24.5 months (range 1-75 months). Twelve patients received CsA alone or in combination with other immunosuppressives, while the remaining 10 patients received azathioprine and prednisone. Mean serum creatinine fell progressively during pregnancy in both CsA- and azathioprine-treated mothers. Mean CsA dose rose during pregnancy while mean CsA blood concentration fell during the 2nd trimester (P = 0.042). The gestation period ranged from 27 to 40 weeks (35.5 +/- 3.3) with 14 pregnancies ending prematurely prior to 37 weeks. Thirteen deliveries occurred by Caesarian section. Hypertension complicated 10 pregnancies. Birth weight correlated directly with both maternal weight gain (r = 0.57; P less than 0.02) and gestational age (r = 0.9; P less than 0.01). Ten of 23 offspring were below the 10th percentile for weight. Mean birth weight ranged from 0.72 to 3.7 kg (2.3 +/- 0.84 kg). The mean birth weight and gestational age of children born to mothers taking CsA were lower than those in azathioprine treated mothers but these differences were not statistically significant. Successful pregnancy is possible following renal transplantation, although there is a high rate of prematurity, low birth weight, and intrauterine growth retardation. CsA dose requirements may be increased. Maternal risks including hypertension require that such pregnancies be handled by a multidisciplinary team approach.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1412722     DOI: 10.1097/00007890-199209000-00008

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  12 in total

1.  Rat metanephric organ culture in terato-embryology.

Authors:  C Merlet-Bénichou; T Gilbert; J Vilar; E Moreau
Journal:  Cell Biol Toxicol       Date:  1996-12       Impact factor: 6.691

2.  Pregnancy in Irish renal transplant recipients in the cyclosporine era.

Authors:  M A Little; K A Abraham; J Kavanagh; G Connolly; P Byrne; J J Walshe
Journal:  Ir J Med Sci       Date:  2000 Jan-Mar       Impact factor: 1.568

Review 3.  Stage 1 chronic kidney disease in pregnancy.

Authors:  Tiina Podymow; Phyllis August
Journal:  Obstet Med       Date:  2012-09-17

Review 4.  Reproductive issues in inflammatory bowel disease.

Authors:  Sumona Saha; Silvia Degli Esposti
Journal:  Med Health R I       Date:  2009-04

5.  Does pregnancy increase graft loss in female renal allograft recipients?

Authors:  Numan Gorgulu; Berna Yelken; Yasar Caliskan; Aydin Turkmen; Mehmet Sukru Sever
Journal:  Clin Exp Nephrol       Date:  2010-01-22       Impact factor: 2.801

6.  Long-term neurodevelopment of children exposed in utero to ciclosporin after maternal renal transplant.

Authors:  Irena Nulman; Michael Sgro; Maru Barrera; David Chitayat; John Cairney; Gideon Koren
Journal:  Paediatr Drugs       Date:  2010-04-01       Impact factor: 3.022

Review 7.  Drug safety issues in pregnancy following transplantation and immunosuppression: effects and outcomes.

Authors:  V T Armenti; M J Moritz; J M Davison
Journal:  Drug Saf       Date:  1998-09       Impact factor: 5.606

Review 8.  Safety and efficacy of immunomodulators and biologics during pregnancy and lactation for the treatment of inflammatory bowel disease.

Authors:  Sumona Saha; Arnold Wald
Journal:  Expert Opin Drug Saf       Date:  2012-09-06       Impact factor: 4.250

Review 9.  Optimisation of antirheumatic drug treatment in pregnancy.

Authors:  M Ostesen
Journal:  Clin Pharmacokinet       Date:  1994-12       Impact factor: 6.447

10.  Use of cyclosporine in uterine transplantation.

Authors:  Srdjan Saso; Karl Logan; Yazan Abdallah; Louay S Louis; Sadaf Ghaem-Maghami; J Richard Smith; Giuseppe Del Priore
Journal:  J Transplant       Date:  2011-11-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.